• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精准医学在预测炎症性肠病结局和控制组织重塑中的未来。

The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.

机构信息

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Gastroenterology, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom.

St Mark's Academic Institute, London North West University Hospitals National Health Service Trust, London, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.

出版信息

Gastroenterology. 2022 Apr;162(5):1525-1542. doi: 10.1053/j.gastro.2021.09.077. Epub 2022 Jan 4.

DOI:10.1053/j.gastro.2021.09.077
PMID:34995532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8983496/
Abstract

Inflammatory bowel disease is characterized by significant interindividual heterogeneity. With a wider selection of pharmacologic and nonpharmacologic interventions available and in advanced developmental stages, a priority for the coming decade is to determine accurate methods of predicting treatment response and disease course. Precision medicine strategies will allow tailoring of preventative and therapeutic decisions to individual patient needs. In this review, we consider the future of precision medicine in inflammatory bowel disease. We discuss the critical need to extend from research focused on short-term symptomatic response to integrative multi-omic systems biology strategies to identify and validate biomarkers that underpin precision approaches. Crucially, the international community has collective responsibility to provide well-phenotyped and -curated longitudinal datasets for scientific discovery and validation. Research must also study broader aspects of the immune response, including components of the extracellular matrix, to better understand biological pathways initiating and perpetuating tissue fibrosis and longer-term disease complications.

摘要

炎症性肠病的特点是个体间存在显著异质性。随着可供选择的药物和非药物治疗方法越来越多,且处于高级发展阶段,未来十年的当务之急是确定准确的方法来预测治疗反应和疾病进程。精准医学策略将使预防和治疗决策能够针对个体患者的需求进行调整。在这篇综述中,我们探讨了炎症性肠病精准医学的未来。我们讨论了从关注短期症状反应的研究扩展到整合多组学系统生物学策略的迫切需要,以确定和验证支持精准方法的生物标志物。至关重要的是,国际社会有共同的责任为科学发现和验证提供表型良好且经过精心整理的纵向数据集。研究还必须研究免疫反应的更广泛方面,包括细胞外基质的组成部分,以更好地了解启动和持续组织纤维化和长期疾病并发症的生物学途径。

相似文献

1
The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.精准医学在预测炎症性肠病结局和控制组织重塑中的未来。
Gastroenterology. 2022 Apr;162(5):1525-1542. doi: 10.1053/j.gastro.2021.09.077. Epub 2022 Jan 4.
2
Challenges in IBD Research: Precision Medicine.炎症性肠病研究的挑战:精准医学。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S31-S39. doi: 10.1093/ibd/izz078.
3
Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review.用于预测生物制剂和小分子疗法对成人炎症性肠病疗效的多组学生物标志物:一项系统评价
United European Gastroenterol J. 2025 May;13(4):517-530. doi: 10.1002/ueg2.12720. Epub 2024 Dec 10.
4
Precision medicine in inflammatory bowel disease: concept, progress and challenges.炎症性肠病中的精准医学:概念、进展与挑战
F1000Res. 2020 Jan 28;9. doi: 10.12688/f1000research.20928.1. eCollection 2020.
5
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.ECCO 第七次科学研讨会:炎症性肠病的精准医学——疾病结局和治疗反应。
J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.
6
Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.基于研究的产品创新,以满足炎症性肠病患者的关键未满足需求。
Inflamm Bowel Dis. 2021 Nov 15;27(Suppl 2):S1-S16. doi: 10.1093/ibd/izab230.
7
Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease.精准医学在多方面炎症性肠病中的整合与实施。
World J Gastroenterol. 2023 Sep 28;29(36):5211-5225. doi: 10.3748/wjg.v29.i36.5211.
8
Impact of artificial intelligence on prognosis, shared decision-making, and precision medicine for patients with inflammatory bowel disease: a perspective and expert opinion.人工智能对炎症性肠病患者预后、共同决策和精准医学的影响:观点和专家意见。
Ann Med. 2023;55(2):2300670. doi: 10.1080/07853890.2023.2300670. Epub 2024 Jan 1.
9
Precision Medicine in Pediatric Inflammatory Bowel Disease.精准医学在小儿炎症性肠病中的应用
Pediatr Clin North Am. 2021 Dec;68(6):1171-1190. doi: 10.1016/j.pcl.2021.07.011.
10
Challenges in IBD Research 2024: Precision Medicine.2024 年炎症性肠病研究面临的挑战:精准医学。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S39-S54. doi: 10.1093/ibd/izae084.

引用本文的文献

1
Glucocorticoid-Mediated Extracellular Matrix Regulation: Implications for Precision Therapy.糖皮质激素介导的细胞外基质调节:对精准治疗的意义。
Biomedicines. 2025 May 23;13(6):1282. doi: 10.3390/biomedicines13061282.
2
Engineered Tissue Models to Decode Host-Microbiota Interactions.用于解码宿主-微生物群相互作用的工程组织模型
Adv Sci (Weinh). 2025 Jun;12(23):e2417687. doi: 10.1002/advs.202417687. Epub 2025 May 14.
3
The relationships between depression, inflammation and self-reported disease activity in IBD and their impact on healthcare usage.

本文引用的文献

1
Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort Study.乌司奴单抗治疗克罗恩病患者的长期临床疗效:一项回顾性队列研究
Crohns Colitis 360. 2020 Jul 28;2(4):otaa061. doi: 10.1093/crocol/otaa061. eCollection 2020 Oct.
2
Incidence and prevalence of inflammatory bowel disease in Devon, UK.英国德文郡炎症性肠病的发病率和患病率
Frontline Gastroenterol. 2020 Jun 24;12(6):461-470. doi: 10.1136/flgastro-2019-101369. eCollection 2021.
3
Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study.
炎症性肠病中抑郁、炎症与自我报告的疾病活动之间的关系及其对医疗保健使用的影响。
BMC Gastroenterol. 2025 Mar 6;25(1):140. doi: 10.1186/s12876-025-03691-8.
4
Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota research.评估肠道活检组织保存方法以促进大规模黏膜微生物群研究。
EBioMedicine. 2025 Feb;112:105550. doi: 10.1016/j.ebiom.2024.105550. Epub 2024 Dec 31.
5
Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis.神经母细胞瘤组学的研究现状与发展趋势:一项文献计量学与可视化分析
Front Oncol. 2024 Oct 10;14:1383805. doi: 10.3389/fonc.2024.1383805. eCollection 2024.
6
Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease.整合多组学以揭示炎症性肠病中的宿主-微生物组相互作用。
Cell Rep Med. 2024 Sep 17;5(9):101738. doi: 10.1016/j.xcrm.2024.101738.
7
Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review.淋巴细胞亚群预测炎症性肠病进展和治疗反应:系统评价。
Front Immunol. 2024 Aug 20;15:1403420. doi: 10.3389/fimmu.2024.1403420. eCollection 2024.
8
PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.基于抗炎肽和免疫抑制剂共组装的靶向肽转运体1的纳米药物用于联合治疗急性和慢性葡聚糖硫酸钠诱导的结肠炎
Front Pharmacol. 2024 Aug 15;15:1442876. doi: 10.3389/fphar.2024.1442876. eCollection 2024.
9
Identification of a Novel Activated NK-Associated Gene Score Associated with Diagnosis and Biological Therapy Response in Ulcerative Colitis.一种与溃疡性结肠炎诊断及生物治疗反应相关的新型活化自然杀伤细胞相关基因评分的鉴定
Digestion. 2025;106(1):1-22. doi: 10.1159/000540939. Epub 2024 Aug 23.
10
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.炎症性肠病靶向治疗的使用趋势:ENEIDA的TRENDY研究
Pharmaceutics. 2024 May 8;16(5):629. doi: 10.3390/pharmaceutics16050629.
超加工食品摄入与炎症性肠病风险的关联:前瞻性队列研究。
BMJ. 2021 Jul 14;374:n1554. doi: 10.1136/bmj.n1554.
4
Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.538 例炎症性肠病患者首用抗 TNF 治疗的有限长期治疗持久性:一项 20 年真实世界研究。
Aliment Pharmacol Ther. 2021 Sep;54(5):667-677. doi: 10.1111/apt.16478. Epub 2021 Jun 20.
5
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.与抗 TNF 生物制剂相比,乌司奴单抗治疗克罗恩病和维得利珠单抗治疗溃疡性结肠炎的持续治疗效果更好:来自真实世界的澳大利亚国家 IBD 队列(PANIC)研究的持久性注册数据。
Aliment Pharmacol Ther. 2021 Aug;54(3):292-301. doi: 10.1111/apt.16436. Epub 2021 Jun 20.
6
Calprotectin: from biomarker to biological function.钙卫蛋白:从生物标志物到生物学功能。
Gut. 2021 Oct;70(10):1978-1988. doi: 10.1136/gutjnl-2021-324855. Epub 2021 Jun 18.
7
Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.系统评价:肠道微生物群及其在炎症性肠病中的潜在临床应用
Microorganisms. 2021 Apr 30;9(5):977. doi: 10.3390/microorganisms9050977.
8
Challenges and Opportunities in IBD Clinical Trial Design.炎症性肠病临床试验设计中的挑战与机遇
Gastroenterology. 2021 Aug;161(2):400-404. doi: 10.1053/j.gastro.2021.03.065. Epub 2021 Apr 20.
9
Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways.单核细胞 TREM-1 水平通过自噬和 Fcγ 受体信号通路与 IBD 对 TNF 抑制剂的反应性相关。
Front Immunol. 2021 Mar 15;12:627535. doi: 10.3389/fimmu.2021.627535. eCollection 2021.
10
Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study.炎症性肠病患者的抑郁和焦虑患病率及相关医疗保健利用情况:基于人群的队列研究
Evid Based Ment Health. 2021 Mar 30;24(3):102-9. doi: 10.1136/ebmental-2020-300223.